SOMARATNE, RANSI MUDALINAYAKE,SCOTT, ROBERT ANDREW DONALD,WASSERMAN, SCOTT,HONARPOUR, NARIMON,NICHOLLS, STEPHEN
申请号：
CA3043700
公开号：
CA3043700A1
申请日:
2017.11.13
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Provided herein are combinations of therapies that provide for the treatment, including regression, of atherosclerosis and/or improvement of cardiovascular outcomes. Generally described, this includes a first, non-PCSK9 LDL-C lowering agent (such as a statin or other non-PCSK9 LDL-C lowering therapy), combined with a second, PCSK9 inhibitor therapy (such as a PCSK9 antibody or anti-RNA). The application of both therapies, at adequately elevated levels so as to reduce the LDL-C level of the subject to very low levels, for an adequate period of time, has been determined to provide an added benefit of further protection from atherosclerosis and improve a subjects cardiovascular outcomes.
